Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy.

Valis, Martin; Ryska, Pavel; Halúsková, Simona; Klímová, Blanka; Pavelek, Zbysek.
BMC Neurol; 20(1): 202, 2020 May 21.
Artigo em Inglês | MEDLINE | ID: mdl-32438901